

Contents

	<i>Page</i>
Foreword	<i>iii</i>
Explanatory notes	<i>ix</i>
<i>Chapter</i>	
I. Cannabis and cannabinoids for medical, scientific and “recreational” use: risks and benefits	1
A. Cannabis, its derivatives and the international drug control conventions	2
B. Pharmaceutical registration and prescription regimes	3
C. Medical uses of cannabinoids	4
D. Adverse effects of short-term medicinal cannabinoid use	5
E. Adverse effects of long-term use of cannabis and its derivatives	6
F. Medical use of approved cannabinoids	6
G. Special-access schemes for medicinal cannabinoids	8
H. Poorly regulated medical cannabis programmes in North America	8
I. Adverse public health effects of medical cannabis programmes	10
J. Legalization of non-medical cannabis use	10
K. Implications for international drug control	11
L. Conclusions and recommendations	12
II. Functioning of the international drug control system	13
A. Promoting the consistent application of the international drug control treaties	13
B. Ensuring the implementation of the provisions of the international drug control treaties	14
C. Governments’ cooperation with the Board	21
D. Evaluation of overall treaty compliance	24
E. Action taken by the Board to ensure the implementation of the international drug control treaties	38
F. Special topics	42
III. Analysis of the world situation	47
Highlights	47
A. Africa	49
B. Americas	54
Central America and the Caribbean	54
North America	58
South America	66
C. Asia	74
East and South-East Asia	74
South Asia	79
West Asia	86
D. Europe	96
E. Oceania	104

IV.	Recommendations to Governments, the United Nations and other relevant international and national organizations	109
Annexes		
I.	Regional and subregional groupings used in the report of the International Narcotics Control Board for 2018.....	115
II.	Current membership of the International Narcotics Control Board	119